(NASDAQ: MRSN) Mersana Therapeutics's forecast annual revenue growth rate of -7.31% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Mersana Therapeutics's revenue in 2024 is $38,298,000.On average, 4 Wall Street analysts forecast MRSN's revenue for 2024 to be $4,911,212,929, with the lowest MRSN revenue forecast at $1,131,841,433, and the highest MRSN revenue forecast at $8,565,286,520. On average, 3 Wall Street analysts forecast MRSN's revenue for 2025 to be $4,853,580,787, with the lowest MRSN revenue forecast at $4,282,643,260, and the highest MRSN revenue forecast at $5,237,060,901.
In 2026, MRSN is forecast to generate $3,059,030,900 in revenue, with the lowest revenue forecast at $3,059,030,900 and the highest revenue forecast at $3,059,030,900.